The emergence of multi-drug resistant (MDR) human bacterial pathogens during 1990s and more recently the extensively resistant clinical isolates is hampering efforts to control and manage human infections by these organisms. Continuous increase in the global isolation rates of Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and carbapenem-resistant Gram negative bacilli clinical isolates poses a serious therapeutic problem. Antimicrobialresistant infections currently claim at least 50,000 lives each year across Europe and the US alone, with many hundreds of thousands more dying in other areas of the world. The scenario is more complicated with emerging resistance to treatments for serious diseases, such as TB, malaria and HIV. By 2050, 10 million more people would be expected to die every year than would be the case if resistance was kept to today’s level